SCHEMBL7646271

SCHEMBL7646271

c1ccc2c(-n3ccnc3)nccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.52
CYP3A4 P08684 9/20 0.48
CYP1A2 P05177 8/20 0.48
LMNA P02545 7/20 0.48
CYP2D6 P10635 7/20 0.48
CYP2C19 P33261 7/20 0.48
TDP1 Q9NUW8 5/20 0.48
HSD17B10 Q99714 4/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HRH4 Q9H3N8 1/20 0.47
HTR2C P28335 1/20 0.47
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
CYP19A1 P11511 1/20 0.47
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
USP2 O75604 5/20 0.46
CLK4 Q9HAZ1 4/20 0.46
TP53 P04637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202901 0.82 COMT (0.58) COMTCYP3A4LMNACYP2C19MAPT
SCHEMBL1536286 0.77 CYP3A4 (0.47) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL11814264 0.76 CYP3A4 (0.52) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL11814515 0.76 CYP3A4 (0.52) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL14211961 0.75 CYP3A4 (0.50) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL508849 0.75 IDO1 (0.58) CYP3A4CYP1A2LMNACYP2D6CYP2C19
Hydrochloric Acid SCHEMBL28957349 0.74 IDO1 (0.56) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL11809887 0.73 CYP3A4 (0.50) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL11820505 0.73 CYP3A4 (0.53) CYP3A4CYP1A2LMNACYP2D6CYP2C19
SCHEMBL11827141 0.72 CYP3A4 (0.52) CYP3A4CYP1A2LMNACYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3961062-A Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-01 US claimed
CN-107858742-A Bathed and assessed using the TSV of field and Characteristic Contrast 朗姆研究公司 2018-03-30 CN disclosed
CN-104233451-B TSV bath evaluation using field to feature comparisons 朗姆研究公司 2017-11-24 CN disclosed
CN-102170787-B Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies PROTEOTECH INC 2014-11-12 CN disclosed
CN-102170787-A Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies PROTEOTECH INC 2011-08-31 CN disclosed
US-6465486-B1 ALPHA2 ADRENOCEPTOR MODULATORS; HYPERTENSION, GLAUCOMA, SEXUAL DYSFUNCTION, DEPRESSION, ATTENTION DEFICIT HYPERACTIVITY DISORDER, PARKINSONISM, NEED FOR ANESTHESIA, CARDIAC ARRYTHMIA ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-15 US disclosed
US-3961062-A Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed
US-3961062-A Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed
US-3961062-A Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed
US-3914236-A 1-(Imidazole-1-yl)-isoquinolines and process for preparing them HOECHST AG 1975-10-21 US disclosed
US-3914236-A 1-(Imidazole-1-yl)-isoquinolines and process for preparing them HOECHST AG 1975-10-21 US disclosed